Neurotech (ASX: NTI) — Company Overview, News & Financial Data
Neurotech International is a biopharmaceutical company developing neurological solutions, including treatments for autism spectrum disorder.
Neurotech
Neurotech International (ASX:NTI) is a biopharmaceutical company focused on the development and commercialisation of neurological solutions that improve quality of life. The company's lead drug candidate, NTI164, is currently in Phase II clinical trials for the treatment of moderate autism spectrum disorder in children. NTI is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. NTI's operations are centred around its two key projects: the NTI164 clinical trials and the commercialisation of Mente.
Snapshot
Operations
Products and/or services of Neurotech
- NTI164: a potent blend of CBDA and assorted minor cannabinoids, including less than 0.3% THC, offers a distinct mechanism from CBD, actively targeting inflammatory pathways and inhibiting cytokine activity.
- Mente: Mente uses personalised audio feedback and earphones to gently guide the brain into a more relaxed state. Based on autism research and a successful clinical trial, Mente is a soft, easy to use and portable headband that was developed to help those on the autism spectrum improve their ability to relax.
Neurotech executive team
- Mark DaviesExecutive Chairman
- Associate Prof. Carolyn EllawayChief Medical Officer
- Bonni GoldsteinChief Medical Advisor for USA
- Peter James Lawrence GriffithsChief Executive Officer of AAT Research Ltd
- Alessandra Marie GauvinCompany Secretary
Latest news about Neurotech
Neurotech International doses first patient in Phase 3 trial
AustraliaNeurotech International secures $4.5M in placement
AustraliaNeurotech International issues 19.5M unlisted options
AustraliaNeurotech gets ethics approval for Phase 3 study
AustraliaNeurotech International raises $4M to fund paediatric neurology research
Australia
Recent announcements
What Neurotech (NTI) has told the market, newest first.
- Change of Director's Interest Notice
- Annual Report (Typeset)
- Notice of Annual General Meeting/Proxy Form
Key financials
Reported results for Neurotech, in AUD.
- Market cap
- 27.5M
- Revenue (TTM)
- 4.7M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.0
- Dividend yield
- —
- Profit margin
- -138.1%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| — | -11.3M | -6.5M | |
| 2.4M | -11.1M | -10.6M | |
| 2K | -8.8M | -5.1M | |
| 6K | -9M | -7.8M |